Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort. (30th January 2017)

• Record Type: Journal Article
• Authors: Liu, Xiaoran; Li, Huiping; Shao, Bin; Wu, Jianmin; Kong, Weiyao; Song, Guohong; Jiang, Hanfang; Wang, Jing; Wan, Fengling
• Is Part Of: Cancer medicine. Volume 6:Number 3(2017:Mar.)
• Page Start: 547
• Page End: 554
• Publication Date: 2017-01-30
• Subjects: BRCA -- breast cancer -- Chinese -- epidemiology; 616.994005
• DOI: 10.1002/cam4.1004
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Triple‐negative breast cancer (TNBC) accounts for 15–20% of all newly diagnosed breast cancers, and is enriched for germline mutation of BRCA . In Asian patients diagnosed with breast cancer, 268 deleterious mutations of BRCA1 and 242 of BRCA2 have been identified so far, including a reported BRCA1 frameshift mutation (rs80350973), apparently found only in Asian people, with a low prevalence of 0.3–1.7% in different breast cancer cohorts. Here, we reported the high prevalence (7.2%) of rs80350973 among 125 Chinese patients with TNBC, which implies its mutational predilection for certain breast cancer subtypes. Although its low prevalence had not indicated any particular clinical significance in previous studies, our results associated rs80350973 mutation with cell checkpoint malfunction, and was found to be more common in TNBC patients with high Ki‐67 indices ( P = 0.004). As Ki‐67 overexpression is a predictor of poor prognosis in TNBC, inclusion of this mutation into genetic assessments may improve the clinical management of Chinese patients with TNBC. Abstract : (1) A highly penetrate recurrent mutation of BRCA1 (rs80350973) was found in Chinese TNBCs, indicating its mutational predilection in certain molecular subtype of breast cancer; (2) This recurrent mutation was correlated with high ki‐67 index.